Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27113 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Ayalew Tefferi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Mastocytosis, Systemic, Leukemia, Mast-Cell, Hematologic Neoplasms, Mastocytosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
The World Health Organization (WHO) classification system categorizes advanced systemic mastocytosis (SM‐Adv) into aggressive SM (ASM), mast cell leukemia (MCL), and SM with associated hematological neoplasm (SM‐AHN). By contrast, the International Consensus Classification (ICC) requires “immature” MC cytomorphology for the diagnosis of MCL and limits SM‐AHN to myeloid neoplasms (SM‐AMN). The current study includes 329 patients with SM‐Adv (median age 65 years, range 18–88; males 58%): WHO subcategories SM‐AHN ( N = 212; 64%), ASM ( N = 99; 30%), and MCL ( N = 18; 6%); ICC subcategories SM‐AMN ( N = 190; 64%), ASM (N = 99; 33%), and MCL ( N = 9; 3%); WHO‐defined MCL with “mature” MC cytomorphology and SM‐AHN associated with lymphoid neoplasms were operationally labeled as “MCL‐mature” ( N = 9) and SM‐ALN ( N = 22), respectively, and distinguished from ICC‐defined MCL and SM‐AMN. Multivariable analysis that included the Mayo alliance risk factors for survival in SM (age >60 years, anemia, thrombocytopenia, increased alkaline phosphatase) revealed more accurate survival prediction with the ICC versus WHO classification order: (i) survival was significantly worse with MCL‐immature versus MCL‐mature (hazard ratio [HR] 15; p < .01), (ii) prognostic distinction between MCL and SM‐AHN/AMN was confirmed in the context of ICC (HR 9.3; p < .01) but not WHO classification order ( p = .99), (iii) survival was similar between MCL‐mature and SM‐AMN ( p = .18), and (iv) SM‐AMN (HR 1.7; p < .01) but not SM‐ALN ( p = .37) was prognostically distinct from ASM. The current study provides evidence for the independent prognostic contribution of both the ICC system for SM‐Adv and the Mayo alliance risk factors for survival in SM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Texas Tech University Health Sciences Center, El Paso, Texas, USA.
- Division of Hematopathology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Ayalew Tefferi, Aref Al-Kali, Mrinal Patnaik, Kebede Begna, Naseema Gangat, Attilio Orazi, Dong Chen, Animesh Pardanani
Zitieren
APA
Tefferi, A., Abdelmagid, M., Al-Kali, A., Patnaik, M., Hogan, W. J., Begna, K., Gangat, N., Orazi, A., Chen, D., Reichard, K. K., & Pardanani, A. (2024). Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases. American Journal of Hematology. https://doi.org/10.1002/ajh.27113
Vancouver
Tefferi A, Abdelmagid M, Al-Kali A, Patnaik M, Hogan WJ, Begna K, et al. Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases. American Journal of Hematology. 2024. doi:10.1002/ajh.27113
BibTeX
@article{Tefferi2024,
author = {Tefferi, Ayalew and Abdelmagid, Maymona and Al-Kali, Aref and Patnaik, Mrinal and Hogan, William J and Begna, Kebede and Gangat, Naseema and Orazi, Attilio and Chen, Dong and Reichard, Kaaren K and Pardanani, Animesh},
title = {Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27113}
}
EUVIMED